PHASE-II STUDY OF SPIROGERMANIUM IN ADVANCED OVARIAN MALIGNANCY

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (1-2) , 119-120
Abstract
In a phase II trial 18 heavily pretreated patients with advanced ovarian malignancy were treated with spirogermanium, 11 i.m. and seven i.v. Objective responses (partial remission) were obtained in 2 (11%) of the 18 patients, with a remission duration of 5 and 23+ mo., respectively. An additional 4 (22%) patients had stable disease. Each of these 6 patients had a better quality of life. There were few side effects. Myelosuppression, nausea or other gastrointestinal side effects did not occur. Spirogermanium apparently is useful as a palliative chemotherapeutic agent in patients with advanced ovarian malignancy.

This publication has 0 references indexed in Scilit: